Artículos por temáticas

Different physical exercise in the treatment of Alzheimer's disease

Deng T, Yu W, Lü Y.

Psychogeriatrics. 2025 Jan;25(1):e13207. doi: 10.1111/psyg.13207. Epub 2024 Oct 26.

Cognitive behavioural treatment for mild Alzheimer's patients and their caregivers (CBTAC): results of a randomised controlled trial

Forstmeier S, Maercker A, Bohli L, Savaskan E, Roth T.

Aging Ment Health. 2025 Feb;29(2):359-368. doi: 10.1080/13607863.2024.2393748. Epub 2024 Aug 20.

Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD)

Boada M, Neve A, Das B, Wojtowicz J, Huang Z, Bullain S, Watkin M, Lott D, Bittner T, Delmar P, Klein G, Hofmann C, Kerchner GA, Smith J, Baudler M, Fontoura P, Doody RS.

J Alzheimers Dis. 2025 Jan;103(2):528-541. doi: 10.1177/13872877241303644. Epub 2024 Dec 16.

The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care

Dickerson BC, Atri A, Clevenger C, Karlawish J, Knopman D, Lin PJ, Norman M, Onyike C, Sano M, Scanland S, Carrillo M.

Alzheimers Dement. 2025 Jan;21(1):e14337. doi: 10.1002/alz.14337. Epub 2024 Dec 23.

Mitochondrial dysfunction in Alzheimer's disease: a key frontier for future targeted therapies

Wang S, Liao Z, Zhang Q, Han X, Liu C, Wang J.

Front Immunol. 2025 Jan 14;15:1484373. doi: 10.3389/fimmu.2024.1484373. eCollection 2024.

Prospects of induced pluripotent stem cells in treating advancing Alzheimer's disease: A review

Park JJ, Rim YA, Sohn Y, Nam Y, Ju JH.

Histol Histopathol. 2025 Feb;40(2):157-170. doi: 10.14670/HH-18-766. Epub 2024 May 21.

Calcium balance through mutual orchestrated inter-organelle communication: A pleiotropic target for combating Alzheimer's disease

Hossain MK, Chae HJ.

Neurochem Int. 2025 Jan;182:105905. doi: 10.1016/j.neuint.2024.105905. Epub 2024 Nov 19.

The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence

Aisen P, Bateman RJ, Crowther D, Cummings J, Dwyer J, Iwatsubo T, Kosco-Vilbois M, McDade E, Mohs R, Scheltens P, Sperling R, Selkoe D.

Alzheimers Dement. 2025 Jan;21(1):e14342. doi: 10.1002/alz.14342. Epub 2024 Nov 13.

The AβA2V paradigm: From molecular insights to therapeutic strategies in Alzheimer's disease and primary tauopathies

Diomede L, Conz A, Mosconi M, Stoilova T, Paloni M, Salvalaglio M, Cagnotto A, Colombo L, Catania M, Di Fede G, Tagliavini F, Salmona M.

Pharmacol Res. 2025 Jan;211:107563. doi: 10.1016/j.phrs.2024.107563. Epub 2024 Dec 27.

PDE4D inhibitors: Opening a new era of PET diagnostics for Alzheimer's disease

Shi L, Wang X, Si H, Song W.

Neurochem Int. 2025 Jan;182:105903. doi: 10.1016/j.neuint.2024.105903. Epub 2024 Dec 6.

Recent advances in Alzheimer's disease therapy: clinical trials and literature review of novel enzyme inhibitors targeting amyloid precursor protein

Antony D, Sheth P, Swenson A, Smoller C, Maguire K, Grossberg G.

Expert Opin Pharmacother. 2025 Jan;26(1):63-73. doi: 10.1080/14656566.2024.2438317. Epub 2024 Dec 4.

Emerging advances in nano-biomaterial assisted amyloid beta chimeric antigen receptor macrophages (CAR-M) therapy: reducing plaque burden in Alzheimer's disease

Kushwaha N, Panjwani D, Patel S, Ahlawat P, Yadav MR, Patel AS.

J Drug Target. 2025 Feb;33(2):185-205. doi: 10.1080/1061186X.2024.2417012. Epub 2024 Oct 21.

A critical review of brexpiprazole oral tablets as the first drug approved to treat agitation symptoms associated with dementia due to Alzheimer's disease

Zhong K, Cummings J.

Expert Rev Neurother. 2025 Jan;25(1):5-13. doi: 10.1080/14737175.2024.2407836. Epub 2024 Sep 29.

Advances in the structural modification of Alzheimer's disease drug - Huperzine A

Zhu X, Xu JB, Gao F, Wan LX.

Bioorg Chem. 2025 Jan;154:108012. doi: 10.1016/j.bioorg.2024.108012. Epub 2024 Nov 29.

Efficacy And Safety of Dual Orexin Receptor Antagonist (DORA) For Sleep Disturbance in Patients With Alzheimer's Disease Dementia. A Review Article

Alshiban A, Hasoglu T, Oster J.

Am J Geriatr Psychiatry. 2025 Feb;33(2):209-218. doi: 10.1016/j.jagp.2024.09.016. Epub 2024 Oct 3.